M
Marc-Henri Stern
Researcher at Curie Institute
Publications - 196
Citations - 12240
Marc-Henri Stern is an academic researcher from Curie Institute. The author has contributed to research in topics: Gene & Breast cancer. The author has an hindex of 49, co-authored 168 publications receiving 9402 citations. Previous affiliations of Marc-Henri Stern include Necker-Enfants Malades Hospital & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor
G.A. Franzetti,Karine Laud-Duval,Dorine Bellanger,Marc-Henri Stern,Xavier Sastre-Garau,Olivier Delattre +5 more
TL;DR: It is shown that miR-30a-5p constitutes a major functional link between EWS-FLI1 and CD99, two critical biomarkers and therapeutic targets in Ewing sarcoma.
Journal ArticleDOI
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Emma I. Andersson,S. Pützer,Bhagwan Yadav,Olli Dufva,Sofia Khan,Liye He,Leopold Sellner,Leopold Sellner,Alexandra Schrader,Giuliano Crispatzu,Małgorzata Oleś,Henan Zhang,Shady Adnan-Awad,Sonja Lagström,Dorine Bellanger,J P Mpindi,Samuli Eldfors,Tea Pemovska,Paavo Pietarinen,Anneli Lauhio,Katarzyna Tomska,Katarzyna Tomska,Carlos Cuesta-Mateos,Edgar Faber,Steffen Koschmieder,T H Brümmendorf,Soili Kytölä,Eeva-Riitta Savolainen,Timo Siitonen,Pekka Ellonen,Olli Kallioniemi,Krister Wennerberg,Wei Ding,Marc-Henri Stern,Wolfgang Huber,Simon Anders,Jing Tang,Jing Tang,Tero Aittokallio,Tero Aittokallio,Thorsten Zenz,Thorsten Zenz,Marco Herling,Satu Mustjoki +43 more
TL;DR: It is found that genetic markers do not readily translate into novel effective therapeutic vulnerabilities, and novel classes of compounds with high efficacy in T-PLL were discovered with the comprehensive ex vivo drug screening platform warranting further studies of synergisms and clinical testing.
Journal ArticleDOI
Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma
Jordan Madic,Sophie Piperno-Neumann,Vincent Servois,Aurore Rampanou,Maud Milder,Bénédicte Trouiller,David Gentien,Stéphanie Saada,Franck Assayag,Aurélie Thuleau,Fariba Nemati,Didier Decaudin,François-Clément Bidard,Laurence Desjardins,Pascale Mariani,Olivier Lantz,Marc-Henri Stern +16 more
TL;DR: Bi-PAP assays detect and quantify ctDNA in patients with metastatic uveal melanoma as a marker of tumor burden and monitor treatment efficacy.
Journal ArticleDOI
Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
François-Clément Bidard,François-Clément Bidard,François-Clément Bidard,Nicolas Kiavue,Marc Ychou,Luc Cabel,Luc Cabel,Luc Cabel,Marc-Henri Stern,Jordan Madic,Adrien Saliou,Aurore Rampanou,Charles Decraene,Olivier Bouché,Michel Rivoire,François Ghiringhelli,Eric Francois,Rosine Guimbaud,Laurent Mineur,Faiza Khemissa-Akouz,Thibault Mazard,Driffa Moussata,Charlotte Proudhon,Jean-Yves Pierga,Jean-Yves Pierga,Trevor Stanbury,Simon Thezenas,Pascale Mariani +27 more
TL;DR: In CRC patients with limited metastatic spread, ctDNA could be used as liquid biopsy tool and could help to select patients eligible for LM resection, according to the clinical validity of circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) detection.
Journal ArticleDOI
Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage
Samar Alsafadi,Alexandre Houy,Aude Battistella,Tatiana Popova,Michel Wassef,Emilie Henry,Franck Tirode,Angelos Constantinou,Sophie Piperno-Neumann,Sergio Roman-Roman,Martin Dutertre,Marc-Henri Stern +11 more
TL;DR: In this paper, the authors used RNA-Seq analyses of uveal melanoma to show that SF3B1(R625/K666) mutation results in deregulated splicing at a subset of junctions, mostly by the use of alternative 3'ss.